Max S. Wicha
Max Wicha identified breast cancer stem cells and made them a therapeutic target.
Co-authored the 2003 paper isolating tumorigenic breast cancer cells, founded Michigan's cancer centre, and studies stem-cell pathways such as IL-6/STAT3 and Notch.
| Title | Journal | Year |
|---|---|---|
| Prospective identification of tumorigenic breast cancer cells | PNAS | 2003 |
Pages like this
not linked directly; found by shared links- PersonLori J. Pierce
Shares University of Michigan Rogel Cancer Center, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.
- IdeaCheap perioperative beta-blocker plus anti-inflammatory to blunt surgical stress
Shares Epithelial–mesenchymal transition & drug efflux, HR-positive / HER2-negative breast cancer.
- IdeaEfflux-agnostic therapy for mesenchymal TNBC
Shares Epithelial–mesenchymal transition & drug efflux, Triple-negative breast cancer (TNBC).
- IdeaSoften the tissue that new metastases need in order to grow
Shares Epithelial–mesenchymal transition & drug efflux, HR-positive / HER2-negative breast cancer.
- IdeaStrip the platelet coat off travelling tumour cells in ctDNA-positive patients
Shares Epithelial–mesenchymal transition & drug efflux, HR-positive / HER2-negative breast cancer.
- PathwayBasement membrane & tissue barriers
Shares Epithelial–mesenchymal transition & drug efflux, HR-positive / HER2-negative breast cancer.
- RoadmapTNBC roadmap: from 'nothing to target' to ADC + immunotherapy first line
Shares Epithelial–mesenchymal transition & drug efflux, Triple-negative breast cancer (TNBC).
- TargetTROP2
Shares Epithelial–mesenchymal transition & drug efflux, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.